Purdue University is investing some $60 million in its life sciences program, with aims to boost research in fields like integrative neurosciences, inflammation, immunology and infectious diseases.
Given the presence of big pharma like Pfizer in the state, this is a noteworthy investment from the university to bulk up its life sciences reputation. Purdue will also invest separately in precision medicine, pharmacophenomics, biological big data science, and toxicological sciences and engineering.
“The life sciences are a critical part of our considerable research portfolio and enhancing our impact and reputation in this area is of significance to Purdue’s future,” President Mitch Daniels said in a statement.
When Investment Rhymes with Canada
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
The dollars will go towards attracting high-profile faculty and buying advanced instrumentation – as well as upgrading the life sciences facilities at the university. The idea is to build up the university’s
This Life Sciences Initiative is a part of Purdue’s broader, $2 billion “Ever True” capital campaign.
